Ambry Genetics And PacBio Selected By UCI And GREGoR Consortium To Support Pediatric Mendelian Genomics Research Center Program To Study Rare Diseases
Ambry Genetics And PacBio Selected By UCI And GREGoR Consortium To Support Pediatric Mendelian Genomics Research Center Program To Study Rare Diseases
UCI和GreGor联盟选中Ambry Genetics和PacBio来支持儿科孟德尔基因组学研究中心研究罕见疾病的计划
- Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies' selection by the University of California, Irvine (UCI) and the GREGoR Consortium (Genomics Research to Elucidate the Genetics of Rare diseases) to support the Pediatric Mendelian Genomics Research Center (MGRC) program to better understand the underlying biology of rare diseases.
- 临床基因组测试领域的杰出领导者、REALM IDx, Inc. 的子公司Ambry Genetics以及高质量、高精度测序解决方案的领先开发商PacBio（纳斯达克股票代码：PACB）今天宣布，加州大学尔湾分校（UCI）和格雷戈联盟（阐明罕见疾病遗传学的基因组学研究）选择了他们的公司来支持小儿孟德尔基因组 ICS研究中心（MGRC）计划旨在更好地了解罕见疾病的潜在生物学。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。